Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
BOSTON, Feb. 16, 2016 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will participate in two upcoming investor conferences:
- Participation in the SunTrust Robinson Humphrey 2016 Orphan Drug Day in New York on Tuesday, February 23, 2016
- Presentation at the 2016 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, February 24, 2016 at 9:30 a.m. ET
A live audio webcast and replay of the RBC presentation will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
